• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS )

    1.360 UNCHANGED
    Streaming Delayed Price Updated: 12:22 PM EDT, Jun 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,612
    Open 1.380
    Bid (Size) 1.340 (74)
    Ask (Size) 1.380 (2)
    Prev. Close 1.360
    Today's Range 1.340 - 1.392
    52wk Range 1.210 - 5.000
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
    From Barinthus Biotherapeutics
    Via GlobeNewswire

    Performance

    YTD
    -63.24%
    -63.24%
    1 Month
    -39.82%
    -39.82%
    3 Month
    -43.33%
    -43.33%
    6 Month
    -61.36%
    -61.36%
    1 Year
    -66.83%
    -66.83%

    More News

    Read More
    Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Biotherapeutics: Q4 Earnings Insights
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
    Via Benzinga
    Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    New partnership aims to advance vaccine against MERS coronavirus
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
    From Barinthus Biotherapeutics
    Via GlobeNewswire
    Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.